Agustin Gago
Corporate Officer/Principal at Syncromune, Inc.
Net worth: - $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eamonn Hobbs | M | 65 |
Syncromune, Inc.
 Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.
E-Z-EM, Inc.
 E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 21 years |
| Douglas G. Watson | M | 79 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
| Charles Link | M | 64 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | 4 years |
| Marlene Wright Barton | F | - |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | 3 years |
| Norman Schwartz | M | 74 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
| Joseph C. Maroon | M | 83 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
| Jeffrey L. Cleland | M | 59 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
| Gregory Champion | M | 69 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
| Johnny John | M | 60 | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter J. Graham | M | 57 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 17 years |
| John Purpura | M | 62 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 17 years |
| Jennifer Simpson | M | 55 | 8 years | |
| Graham Miao | M | 60 | 3 years | |
| Kin Yip Leung | M | 63 | 3 years | |
| William M. Appling | M | 61 | 3 years | |
| Richard Taney | M | 68 | 4 years | |
| Sol Barer | M | 76 | 6 years | |
| Laura Brege | F | 66 | 2 years | |
| David McDonald | M | 63 | 4 years | |
| Anastasios Konidaris | M | 57 | 2 years | |
| Robert Ladd | M | 65 | 6 years | |
| Isaac Blech | M | 73 | 1 years | |
| Brad S. Schreck | M | 67 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | - |
| J. Chris Houchins | M | 61 | - | |
| John Blanchette | M | - | - | |
| Daniel S. Johnston | M | - | - | |
| Harold C. Mapes | M | 64 | 2 years | |
| Armand Frigon | M | - | - | |
| James Thrall | M | 80 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 3 years |
| Bernard R. Tyrrell | M | - | - | |
| Adel Michael | M | 80 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 1 years |
| George P. Ward | M | 86 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 6 years |
| Gloria T. Lee | M | 73 | - | |
| Michael D. Dellario | M | - | - | |
| Robert J. Beckman | M | 76 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 6 years |
| Dennis J. Curtin | M | 77 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | - |
| Howard S. Stern | M | 93 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | - |
| John Preston | M | 74 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 36 | 94.74% |
| Israel | 2 | 5.26% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Agustin Gago
- Personal Network
